首页|Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy
Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Wiley
Highly effective modulator therapy (HEMT) for cystic fibrosis (CF) has been touted as one of the greatest advances to date in CF care. As these therapies are now available for many older children and adults with CF, marked improvement of their nutritional status, pulmonary and gastrointestinal symptoms has been observed. However, most infants and younger children are not current candidates for HEMT due to age and/or cystic fibrosis transmembrane conductance regulator (CFTR) mutation. For these young children, it is essential to provide rigorous monitoring and care to avoid potential disease sequelae while awaiting HEMT availability. The following article highlights recent advances in the care of infants and young children with CF with regard to surveillance and treatment of nutritional, pulmonary, and gastrointestinal disorders. Recent clinical trials in this population are also reviewed.
NSTL
Wiley
